Last reviewed · How we verify
WINREVAIR — Competitive Intelligence Brief
marketed
activin A and other TGF-β superfamily ligands
Other
Live · refreshed every 30 min
Target snapshot
WINREVAIR (SOTATERCEPT-CSRK) — MERCK SHARP DOHME. Sotatercept-csrk binds to activin A and other TGF-β superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| WINREVAIR TARGET | SOTATERCEPT-CSRK | MERCK SHARP DOHME | marketed | activin A and other TGF-β superfamily ligands |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). WINREVAIR — Competitive Intelligence Brief. https://druglandscape.com/ci/sotatercept-csrk. Accessed 2026-05-26.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab